Raymond James Financial
TTNP

Raymond James Financial’s Titan Pharmaceuticals TTNP Stock Holding History

Raymond James Financial’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1
Closed -$4 – 6652
2025
Q2 		$4 Buy
+1
New +$4 ﹤0.01% 6964

Other funds holding TTNP

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GWSA
Global Wealth Strategies & Associates Denver, Colorado $528M AUM 23.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James Financial's TTNP Position: Q3 2025 in Review

Raymond James Financial sold out of Titan Pharmaceuticals (TTNP) in Q3 2025, closing a stake of 1 share — an estimated $4 sold.

Raymond James Financial first reported a position in TTNP in Q2 2025 and held it in 1 quarter. The position peaked at $4 in Q2 2025. 18 funds tracked by Wall St. Rank hold TTNP as of Q3 2025.

  • Raymond James Financial reported no remaining Titan Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 1 Titan Pharmaceuticals share in Q3 2025, an estimated $4.
  • Raymond James Financial first reported a position in Titan Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Titan Pharmaceuticals position peaked at $4 in Q2 2025.
  • 18 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.